Treatment of recurrent small cell lung cancer / 国际肿瘤学杂志

ABSTRACT

Small-cell lung cancer (SCLG) relapses in the majority of patients,even though most patients respond to first-line therapy.Subsequent therapy can provide significant palliation and prolongation of survival for many patients. At present,topotecan is considered the standard second-line chemotherapy.Recently,amrubicin has also shown more favorable antitumor activity,and is the most promising at present.Unfortunately,targeted agents have failed to demonstrate effectiveness for SCLC.